You've heard about the likes of Ozempic, Wegovy and Mounjaro, jabs which a growing number of people are taking in an attempt ...

AstraZeneca spinout Dizal Pharmaceuticals won an FDA accelerated approval for sunvozertinib for previously treated EGFR ex 20-mutated non-small cell lung cancer. To be marketed as Zegfrovy, the oral ...

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...

Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...

the emergence of a viable local alternative to Novo and Lilly’s blockbuster GLP-1 treatments could make weight loss drugs more accessible in the world’s second-largest economy. China’s nascent weight ...

‘China’s Ozempic’ may vie with Eli Lilly, Novo Nordisk for global weight-loss drug market. ... I expect three to five more drugs in this category to be approved within five years,” he said.

To put that in perspective, the highest dose of Zepbound, Eli Lilly’s injectable GLP-1 drug approved for obesity management, leads to an almost 15% weight loss in adults with Type 2 diabetes ...

Eli Lilly's stock boomed April 17 after announcing a new experimental pill that caused nearly 8% weight loss at certain dosages and lowered blood sugar in patients during a clinical trial.. The ...

Eli Lilly, the drugmaker behind the blockbuster weight loss drug Zepbound, is suing four telehealth companies for allegedly selling illegal copies of the drug made by compounding pharmacies ...

Patients taking Eli Lilly’s drug to combat obesity, Zepbound, lost more weight than those who took Novo Nordisk’s Wegovy in a head-to-head study.

Some drugs initially approved to treat Type 2 diabetes are now being used for cosmetic weight loss. WSJ’s Daniela Hernandez explains how they work, their side effects, and concerns over ...